Live feed14:17:00·862dPRReleasevia QuantisnowBioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.ByQuantisnow·Wall Street's wire, on your screen.HRZN· Horizon Technology Finance CorporationFinance